The year 2024 has been a transformative period for biotechnology and gene therapy, with groundbreaking developments improving patient outcomes and expanding access to life-saving treatments.
read moreRNA-based technologies include messenger RNA (mRNA), RNA interference (RNAi), and the emerging circular RNA (circRNA), each offering a unique pathway to address genetic and protein-level diseases effectively.
read moreTherapeutic innovations are as diverse as the challenges they address—ranging from gene and cell therapies to mRNA-based treatments and next-generation biologics.
read moremRNA technology has emerged as a transformative force in the biopharmaceutical industry, enabling groundbreaking therapies and vaccines, including those for COVID-19.
read moreAdvanced therapies, particularly cell and gene therapies, are ushering in a new era of personalized medicine, offering hope for patients with previously untreatable diseases.
read moreWhat is the perfect recipe that delivers the maximum result?
read moreWhat is the perfect recipe that delivers the maximum result?
read moreWorking in a Biotech Manufacturing Organization means joining a team of talented professionals focused on innovation, continuous growth, and a shared mission to improve lives.
read moreAnemocyte offers plasmid DNA (pDNA) manufacturing covering R&D, High Quality and GMP needs providing solutions that support every stage of therapy development while ensuring rigorous quality and traceability.
read moreQuality assurance (QA) is crucial in the manufacturing of plasmid DNA (pDNA), a key component in gene therapy, vaccine development, genome editing, and synthetic biology.
read more
Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961
